These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38241776)

  • 21. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
    Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
    J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.
    Rosager AM; Dahlrot RH; Sørensen MD; Bangsø JA; Hansen S; Kristensen BW
    J Neuropathol Exp Neurol; 2022 Jan; 81(1):54-60. PubMed ID: 34875075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
    Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
    Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.
    Fukai J; Arita H; Umehara T; Yoshioka E; Shofuda T; Kanematsu D; Kodama Y; Mano M; Kinoshita M; Okita Y; Nonaka M; Uda T; Tsuyuguchi N; Sakamoto D; Uematsu Y; Nakao N; Mori K; Kanemura Y
    Brain Tumor Pathol; 2020 Apr; 37(2):50-59. PubMed ID: 32361941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
    J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
    Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
    Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of P53 promotes nucleus pulposus cell apoptosis in intervertebral disc degeneration through upregulating NDRG2.
    Zhang K; Zhang Y; Zhang C; Zhu L
    Cell Biol Int; 2021 Sep; 45(9):1966-1975. PubMed ID: 34051015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
    Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
    Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
    Kessler R; Fleischer M; Springsguth C; Bigl M; Warnke JP; Eschrich K
    J Neuropathol Exp Neurol; 2019 Sep; 78(9):865-870. PubMed ID: 31369092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer.
    Wei Y; Yu S; Zhang Y; Zhang Y; Zhao H; Xiao Z; Yao L; Chen S; Zhang J
    Oncotarget; 2017 Apr; 8(17):29038-29047. PubMed ID: 28423695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas.
    Dénes A; Bontell TO; Barchéus H; Vega SF; Carén H; Lindskog C; Jakola AS; Smits A
    PLoS One; 2023; 18(5):e0285732. PubMed ID: 37192181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
    Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.